Morepen Laboratories Ltd
Morepen Laboratories Ltd Q1 FY27 Results & Presentation Highlights: Revenue, Margins & Order Book
Q1 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Morepen Laboratories Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Quarterly revenue reported: Rs. EBITDA for Q1 FY27: Rs.
From Morepen Laboratories Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
2 more points management made on revenue & sales performance
Profitability & Margins
See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capacity expansion roadmap from 600 KL to 1200 KL (Page 17).
- Manufacturing capacity scaling in four phases:
- Phase 1: 535 KL (completed by Q4 FY26)
- Phase 2: 600 KL (Q2 FY27)
- Phase 3: 800 KL (FY29)
- Phase 4: 1000 KL (Q2 FY28) and 1200 KL (FY30) (Page 11).
- No specific capex amount mentioned.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Morepen Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹485 Cr, net profit ₹16 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Morepen Laboratories Ltd's management said in earlier quarters
- Q1 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q4 FY22 earnings call →
- Q3 FY22 earnings call →
- Q2 FY22 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Procter & Gamble Health Ltd (Q1 FY27)
FY 2025-26 sales grew by +16% year-on-year, indicating strong consistent balanced growth (Page 8). Key investor presentation takeaways from Procter & Gamble Hea
- Jubilant Pharmova Ltd (Q1 FY27)
2,229 Cr., up 17% YoY (Page 97) . Key investor presentation takeaways from Jubilant Pharmova Ltd's Q1 FY27 investor presentation — and how it ranks against sect
- Beta Drugs Ltd (Q1 FY27)
Q1-FY27 revenue from operations: INR 1,255 Mn, up 25.2% YoY from INR 1,002 Mn in Q1-FY26 (Page 32). Key investor presentation takeaways from Beta Drugs Ltd's Q1
- NGL Fine Chem Ltd (Q1 FY27)
Quarterly Revenue (Q1FY27):** ₹139.16 crores . Key investor presentation takeaways from NGL Fine Chem Ltd's Q1 FY27 investor presentation — and how it ranks aga
Frequently Asked Questions
What were Morepen Laboratories Ltd Q1 FY27 results?
Quarterly revenue reported: Rs. EBITDA for Q1 FY27: Rs.
What is Morepen Laboratories Ltd share price analysis?
Morepen Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 56.4 with a market cap of ₹6,625 Cr. Investors should review the full earnings analysis for detailed insights.
Is Morepen Laboratories Ltd planning capital expenditure?
Capacity expansion roadmap from 600 KL to 1200 KL (Page 17).
Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.